SS-31: Research Overview

SS-31 — known in clinical development as elamipretide (and earlier as Bendavia or MTP-131) — is a synthetic tetrapeptide (D-Arg-2′,6′-dimethyltyrosine-Lys-Phe-NH2) from the Szeto-Schiller peptide series. Its defining property is mitochondria targeting: the peptide concentrates selectively in the inner mitochondrial membrane, where it binds cardiolipin. That single interaction has made SS-31 a flagship compound of mitochondrial medicine research, with a development history spanning preclinical models, formal clinical trials, and ongoing investigational programs.

The Szeto-Schiller design

SS-31 emerged in the early 2000s from the peptide program of Hazel Szeto and Peter Schiller, who set out to engineer small peptides that would accumulate in mitochondria. The design — alternating aromatic and basic amino-acid residues, with D-amino-acid substitutions for stability — gives the peptide its membrane-targeting behavior without requiring any delivery vehicle. It crosses cell membranes in research models and partitions into mitochondria at concentrations far above surrounding compartments.

How SS-31 works in research models

The mechanism literature centers on cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane:

• Cardiolipin binding: SS-31 binds cardiolipin selectively. Cardiolipin is essential for the architecture of mitochondrial cristae and for organizing the electron-transport-chain complexes and supercomplexes embedded in that membrane.
• Membrane-structure effects: research describes the interaction stabilizing cristae curvature and supporting electron-transport-chain organization — studied in models where membrane architecture has degraded (aging, ischemia-reperfusion, genetic mitochondrial disease).
• Redox effects: studies report reduced cytochrome-c peroxidase activity and lower reactive-oxygen-species production in models under SS-31 exposure — an antioxidant-adjacent profile achieved through membrane chemistry rather than radical scavenging.

Research timeline and clinical program

Preclinical characterization through the 2000s established the cardiolipin mechanism across ischemia, heart-failure, and aging models. SS-31 then advanced into formal clinical development as elamipretide: the MMPOWER program in primary mitochondrial myopathy, the TAZPOWER trial in Barth syndrome (a genetic cardiolipin-remodeling disorder — the most mechanism-matched indication imaginable), EMBRACE-STEMI in cardiac ischemia-reperfusion research, and PROGRESS-HF in heart-failure populations. Results across these programs were mixed on primary endpoints, and elamipretide remains investigational — not an approved drug. Material supplied for research is laboratory material only.

Key published findings

• Mechanism papers: foundational studies characterized the selective cardiolipin interaction and its effects on membrane potential and ROS in isolated-mitochondria and cell systems.
• Barth syndrome research: the TAZPOWER trial examined functional endpoints in this cardiolipin-disorder population, publishing detailed results that continue to inform mitochondrial-medicine research design.
• Cardiac research: animal heart-failure models reported improved mitochondrial-function and functional markers; human cardiac programs (EMBRACE-STEMI, PROGRESS-HF) published their outcome data in cardiology literature.
• Aging research: preclinical work (including aged-heart models from the Campbell/Rabinovitch research community) reported restoration of mitochondrial-function markers in aged animals — a heavily cited branch of the literature.

Context among related compounds

SS-31 is the structural arm of this library's mitochondrial triad: it targets membrane architecture directly, while MOTS-c is a mitochondrial-encoded signal and NAD+ is the substrate coenzyme. The three are frequently cited together in mitochondrial-medicine literature because they address different failure points of the same organelle.

What researchers examine

Active questions include cardiolipin-interaction biophysics, cristae-remodeling kinetics, ischemia-reperfusion models, aging-mitochondria designs, and combination studies with metabolism-affecting compounds. SS-31's unusually clean mechanism and formal clinical history make it a reference standard for mitochondrial-targeting research.

Frequently asked research questions

What does "mitochondria-targeted" mean?

SS-31's structure causes it to concentrate inside mitochondria — specifically in the inner membrane — rather than distributing generally through the cell. No delivery vehicle is required; targeting is built into the peptide itself.

What is cardiolipin and why does it matter?

A phospholipid unique to the inner mitochondrial membrane, essential for cristae architecture and electron-transport-chain organization. SS-31's selective binding to it is the core of the peptide's research profile.

Is SS-31 (elamipretide) approved?

No. Despite multiple formal clinical programs (Barth syndrome, mitochondrial myopathy, cardiac research), it remains investigational. Material from Prestige Peptides is laboratory research material only, not for human use.

What is the Szeto-Schiller series?

The family of mitochondria-targeted tetrapeptides from Hazel Szeto and Peter Schiller's research program, of which SS-31 is the most extensively studied member.

How is it supplied and verified?

Lyophilized powder in sealed vials, identity and purity verified at ≥99% by independent third-party HPLC analysis.

What is the difference between SS-31 and elamipretide?

They are the same molecule. SS-31 is the laboratory/research name from the Szeto-Schiller series; elamipretide (also Bendavia, MTP-131) is the name used in the formal clinical-development program.

How should the research material be stored?

Lyophilized vials: frozen at -20°C or below for long-term storage, protected from light and moisture. After reconstitution under sterile laboratory conditions, keep refrigerated at 2–8°C and use within the protocol's validated window.

How the evidence base reads

SS-31 has the unusual profile of deep preclinical literature plus completed formal clinical trials (Barth syndrome, mitochondrial myopathy, cardiac programs) — which published mixed primary-endpoint results and left the compound investigational. That full arc is scientifically valuable: researchers can read mechanism, animal models, and human trial data for the same molecule, which is rare in this field.

Laboratory handling and stability

For long-term research storage, keep lyophilized vials frozen at -20°C or below, protected from light and moisture; short-term handling at 2–8°C is standard. Reconstitution should be performed only under sterile laboratory conditions with the laboratory-grade solvent specified by the research protocol, and reconstituted material should be kept cold, protected from light, and used within the validated window of the protocol. Record vial lot numbers and retain the certificate of analysis with study records — traceability is a baseline requirement for reproducible work.

Related research in this library

MOTS-c · NAD+ · Tesamorelin

What the clinical program teaches researchers

SS-31's trial history is instructive beyond the compound itself. Mechanistically, it is among the cleanest mitochondrial-targeting agents ever designed, and the Barth syndrome indication was a near-perfect mechanistic match — a cardiolipin disorder treated with a cardiolipin-binding peptide. Yet trial endpoints were mixed. The lesson the literature draws is translational: membrane biophysics in isolated mitochondria does not guarantee functional endpoints in complex human populations. For research design, that makes SS-31 a benchmark for how mechanism-first compounds should progress through evidence tiers.

Why D-amino acids in the sequence?

The D-arginine and dimethyltyrosine substitutions protect the peptide from enzymatic degradation and tune its membrane-partitioning behavior — stability and targeting engineered into the sequence itself.

Form, handling, and verification

SS-31 is supplied as a lyophilized (freeze-dried) powder in sealed vials, with identity and purity verified at ≥99% by independent third-party HPLC analysis. Lyophilized material should be stored in a cool, dry environment away from light and handled per standard laboratory protocol with appropriate protective equipment.

View SS-31 research material →

Research Use Only. All materials referenced are supplied strictly for qualified in-vitro laboratory research. Not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any disease. Nothing in this article constitutes medical advice, dosing guidance, or a recommendation for human use.